Cerebrolysin vs Dihexa

Cerebrolysin

Cerebrolysin is not a single peptide. It is a standardised enzymatic hydrolysate of purified porcine brain protein containing low-molecular-weight neuropeptides and free amino acids, so no single half-life or molecular weight applies. DOSING CONVENTION: it is supplied as a ready-made sterile solution at 215.2 mg of peptide concentrate per mL, in sealed ampoules of 1, 2, 5, 10 and 20 mL, and it is prescribed in mL, never in mcg. The figures in this entry are the mg equivalents of that solution converted to mcg for consistency with the rest of the dataset: 215,200 mcg = 1 mL, 430,400 mcg = 2 mL, 1,076,000 mcg = 5 mL. It is NOT reconstituted, so the vial sizes above are ampoule contents and the bacteriostatic water field does not apply. Route matters: 5 mL is the practical ceiling for a single intramuscular injection, and the larger doses used in trials (10-50 mL/day) are given as slow intravenous infusions in a clinical setting, not IM. It is approved in a number of European, Asian and CIS countries but is NOT FDA approved. Human evidence is more substantial than for the other compounds in this class - randomized trials and Cochrane reviews in acute ischaemic stroke, vascular dementia, Alzheimer disease and traumatic brain injury - but the results are mixed, the stroke reviews found no convincing benefit on death or dependency, and much of the trial base is manufacturer-sponsored. Courses are conventionally given 5 days a week for about 4 weeks rather than continuously.

Dihexa

THERE IS ESSENTIALLY NO HUMAN DATA ON DIHEXA. It is a small-molecule angiotensin IV analogue developed in an academic laboratory (Washington State University) that potentiates hepatocyte growth factor signaling at its receptor c-Met and promotes synaptogenesis. Every efficacy claim attached to it comes from rodent work: scopolamine-impaired and lesioned rats, and Parkinson and Alzheimer disease models. It has never completed a published human trial, there is no published human pharmacokinetic or toxicology data, and no approved product exists anywhere. Because of that, the range given here is deliberately narrow and conservative: it is derived from what unregulated users report taking (roughly 3-20 mg per day orally or transdermally), NOT from any dose-finding study, and it should be read as a description of practice, not a recommendation. The active-malignancy flag is not a formality: c-Met is a well-characterized oncogenic pathway and chronically potentiating it in a person with an existing or suspected cancer is a real theoretical hazard. It is taken as a powder or in a carrier rather than reconstituted for injection, so the vial and bacteriostatic water fields do not apply in the usual way.